Published in PLoS One on May 16, 2013
Targeting RANKL in metastasis. Bonekey Rep (2014) 0.95
Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol (2014) 0.92
RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metastasis (2013) 0.91
Genetics of breast cancer bone metastasis: a sequential multistep pattern. Clin Exp Metastasis (2014) 0.87
Proteolysis during tumor cell extravasation in vitro: metalloproteinase involvement across tumor cell types. PLoS One (2013) 0.85
Mammary carcinoma with osteoclast-like giant cells: a case report. Int J Clin Exp Pathol (2014) 0.85
Clinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancer. Oncotarget (2016) 0.80
The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases. Oncotarget (2016) 0.79
SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation. Dig Dis Sci (2015) 0.78
Apoptosis signal-regulating kinase 1 is involved in brain-derived neurotrophic factor (BDNF)-enhanced cell motility and matrix metalloproteinase 1 expression in human chondrosarcoma cells. Int J Mol Sci (2013) 0.77
Extracellular Membrane Vesicles Derived from 143B Osteosarcoma Cells Contain Pro-Osteoclastogenic Cargo: A Novel Communication Mechanism in Osteosarcoma Bone Microenvironment. Transl Oncol (2014) 0.77
Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences. J Proteome Res (2016) 0.77
Cancer cells remodel themselves and vasculature to overcome the endothelial barrier. Cancer Lett (2014) 0.76
Hemin activation of innate cellular response blocks human immunodeficiency virus type-1-induced osteoclastogenesis. Biochem Biophys Res Commun (2015) 0.76
A case of long term survival with skeletal only metastatic breast cancer. Int J Surg Case Rep (2014) 0.75
Importance of osteoprotegrin and receptor activator of nuclear factor κB in breast cancer response to hepatocyte growth factor and the bone microenvironment in vitro. Int J Oncol (2016) 0.75
RANK overexpression as a novel esophageal cancer marker: validated immunohistochemical analysis of two different ethnicities. Int J Clin Exp Pathol (2015) 0.75
Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors. PLoS One (2015) 0.75
RANK Ligand Modulation of Autophagy in Oral Squamous Cell Carcinoma Tumor Cells. J Cell Biochem (2016) 0.75
RANKL enhances the effect of an antagonist of inhibitor of apoptosis proteins (cIAPs) in RANK-positive breast cancer cells. J Bone Oncol (2013) 0.75
Myosin isoform expressed in metastatic prostate cancer stimulates cell invasion. Sci Rep (2017) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (1997) 8.59
Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev (2001) 6.57
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
Cancer to bone: a fatal attraction. Nat Rev Cancer (2011) 4.08
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature (2010) 3.66
Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest (1996) 3.44
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev (2009) 2.59
Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem (1998) 2.48
Mechanisms of bone metastasis. Cancer (1997) 2.29
Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology (1999) 2.11
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res (2012) 1.98
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer (2006) 1.75
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res (2007) 1.63
Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer (2009) 1.58
Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett (2008) 1.54
Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res (2001) 1.54
A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem (2002) 1.54
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One (2011) 1.44
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate (2008) 1.42
Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis (2007) 1.32
A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. Bone (2004) 1.29
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol (2011) 1.27
Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res (2005) 1.18
Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol (2002) 1.17
Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases. Biochim Biophys Acta (2007) 1.07
DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Bone (2006) 1.05
Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat (2008) 1.04
Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Res (2013) 1.00
Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol (2007) 0.98
C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway. Oncol Lett (2011) 0.92
Biomarker profile in breast carcinomas presenting with bone metastasis. Int J Clin Exp Pathol (2009) 0.88
Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors. Clin Exp Metastasis (2011) 0.87
A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (2011) 6.16
Cancer to bone: a fatal attraction. Nat Rev Cancer (2011) 4.08
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Helical structures of ESCRT-III are disassembled by VPS4. Science (2008) 3.38
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol (2009) 3.37
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol (2005) 3.31
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst (2005) 3.08
Molecular biology of bone metastasis. Mol Cancer Ther (2007) 2.71
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res (2006) 2.69
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol (2002) 2.55
Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer (2007) 2.55
A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A (2003) 2.23
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res (2010) 2.15
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int (2005) 2.11
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res (2006) 1.99
Differential stem- and progenitor-cell trafficking by prostaglandin E2. Nature (2013) 1.99
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol (2008) 1.98
Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem (2002) 1.95
Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res (2007) 1.89
Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia (2005) 1.75
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer (2013) 1.74
Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One (2009) 1.72
Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer (2004) 1.69
GLI2-mediated melanoma invasion and metastasis. J Natl Cancer Inst (2010) 1.68
TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res (2010) 1.68
Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab (2004) 1.67
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2006) 1.65
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer (2003) 1.65
Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res (2005) 1.65
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res (2011) 1.64
Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One (2008) 1.60
Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer (2008) 1.57
Role of endothelin-1 in osteoblastic bone metastases. Cancer (2003) 1.54
The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest (2003) 1.53
TGF-β/SMAD/GLI2 signaling axis in cancer progression and metastasis. Cancer Res (2011) 1.49
Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer (2012) 1.47
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leuk Res (2009) 1.47
Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol (2006) 1.44
Calcium release channel RyR2 regulates insulin release and glucose homeostasis. J Clin Invest (2015) 1.38
Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol (2004) 1.36
Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res (2010) 1.35
Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem (2003) 1.32
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev (2008) 1.32
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32
The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol (2009) 1.31
Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res (2008) 1.22
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev (2009) 1.22
TGF-β in cancer and bone: implications for treatment of bone metastases. Bone (2010) 1.20
Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol (2002) 1.17
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol (2009) 1.14
Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med (2008) 1.12
Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncol Rep (2007) 1.12
Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest (2002) 1.12
Metastatic breast cancer: overview of treatment. Clin Orthop Relat Res (2003) 1.11
Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer (2008) 1.10
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer (2009) 1.09
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology (2007) 1.08
The role of TGF-β in bone metastasis: novel therapeutic perspectives. Bonekey Rep (2012) 1.06
TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases. Cancer Microenviron (2011) 1.05
Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat (2010) 1.05
HER-2/neu diagnostics in breast cancer. Breast Cancer Res (2007) 1.04
Assessing new bone formation in neonatal calvarial organ cultures. Methods Mol Biol (2008) 1.03
Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev (2008) 1.03
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer. Cancer (2006) 1.02
Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res (2004) 1.02
Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol (2011) 1.01
Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer (2008) 1.00
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res (2008) 1.00
Structure and function of ESCRT-III. Biochem Soc Trans (2009) 0.99
Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer (2012) 0.99
The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. Cancer Lett (2006) 0.98
Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem (2002) 0.98
Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients. Clin Cancer Res (2012) 0.98
GST M1/T1 and MTHFR polymorphisms as risk factors for hypertension. Biochem Biophys Res Commun (2006) 0.97
Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res (2010) 0.97
Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res (2011) 0.97
Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. Oncol Rep (2002) 0.96
Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop Relat Res (2003) 0.95
Anticancer evidence for zoledronic acid across the cancer continuum. Crit Rev Oncol Hematol (2011) 0.95
Zoledronic acid use in cancer patients: more than just supportive care? Cancer (2011) 0.94
Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Res (2001) 0.94
Protein kinase Calpha regulates Ets1 transcriptional activity in invasive breast cancer cells. Int J Oncol (2003) 0.94
MTA1 promotes STAT3 transcription and pulmonary metastasis in breast cancer. Cancer Res (2013) 0.94